胸膜腔内注入重组人血管内皮抑制素（恩度）治疗癌性胸水的临床研究

Clinical Study of Intrapleural Injection of Recombinant Human Endostatin(Endo) in the Treatment of Cancerous Pleural Effusion

目的分析并研究胸膜腔内注入重组人血管内皮抑制素(恩度)治疗癌性胸水的临床疗效。方法该次实验共有84例患者参与实验,所有患者均该院在2016年5月—2018年5月收录治疗的,并将患者随机平均分为对照组和观察组,观察组和对照组均有患者42例,观察组患者使用胸膜腔内注入重组人血管内皮抑制素(恩度)进行治疗,对照组患者使用胸腔注入顺铂40mg进行治疗,对两组患者的临床治疗效果、生活质量评测等指标进行实验统计记录,并对两组患者实验的结果精心对比分析。结果观察组患者的临床有效率为29例(69.04%),对照组患者的临床有效率为22例(52.38%),差异有统计学意义(χ^2=2.4456,P<0.05);观察组患者的疾病控制率为35例(83.33%),对照组患者的临床有效率为28(66.67%),差异有统计学意义(χ^2=3.1111,P<0.05);观察组患者有29例(69.04%)得到了改善,对照组患者有22例(52.38%)得到了改善,差异有统计学意义(χ^2=2.4456,P<0.05)。结论使用胸膜腔内注入重组人血管内皮抑制素(恩度)进行治疗,可以有效缓解癌性胸水患者的临床症状。

Objective To analyze and study the clinical efficacy of intrapleural injection of recombinant human endostatin (Endo) in the treatment of cancerous pleural effusion. Methods A total of 84 patients participated in the trial. All patients were enrolled in our hospital from May 2016 to May 2018. The patients were randomly divided into control group and observation group. Both observation group and control group were included, 42 patients in each group. The patients in the observation group were treated with intrapleural injection of recombinant human endostatin (Endo). The patients in the control group were treated with 40 mg of cisplatin in the thoracic cavity. The clinical treatment effect and quality of life of the two groups were evaluated. The indicators were statistically recorded, and the results of the two groups of patients were carefully compared and analyzed. Results The clinical effective rate of the observation group was 29 cases(69.04%), and the clinical effective rate of the control group was 22 cases(52.38%). The difference was statistically significant (χ^2=2.445 6, P<0.05);observation group of the disease control rate of the patients in the group was 35 cases(83.33%), and the clinical effective rate was 28 cases(66.67%) in the control group. The difference was statistically significant (χ^2=3.111 1, P<0.05), and the observation group of 29 cases(69.04%) was improved, and the control group had 22 cases(52.38%) improved, the difference was statistically significant (χ^2=2.445 6, P<0.05). Conclusion The use of intrapleural injection of recombinant human endostatin (Endo) for treatment can effectively alleviate the clinical symptoms of patients with cancerous pleural effusion.